MATK
Summary: The protein encoded by this gene has amino acid sequence similarity to Csk tyrosine kinase and has the structural features of the CSK subfamily: SRC homology SH2 and SH3 domains, a catalytic domain, a unique N terminus, lack of myristylation signals, lack of a negative regulatory phosphorylation site, and lack of an autophosphorylation site. This protein is thought to play a significant role in the signal transduction of hematopoietic cells. It is able to phosphorylate and inactivate Src family kinases, and may play an inhibitory role in the control of T-cell proliferation. This protein might be involved in signaling in some cases of breast cancer. Three alternatively spliced transcript variants that encode different isoforms have been described for this gene. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| megakaryocyte-associated tyrosine kinase | MIM:600038 | Ensembl:ENSG00000007264 | HGNC:HGNC:6906 | PA30649 | 19p13.3 |
GO terms in MATK
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | TAS | GO:0004713 | protein tyrosine kinase activity |
| MF | IBA | GO:0004715 | non-membrane spanning protein tyrosine kinase activity |
| MF | IBA | GO:0005102 | signaling receptor binding |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0005524 | ATP binding |
| BP | TAS | GO:0006468 | protein phosphorylation |
| BP | IBA | GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway |
| BP | TAS | GO:0007498 | mesoderm development |
| BP | TAS | GO:0008283 | cell proliferation |
| BP | TAS | GO:0008284 | positive regulation of cell proliferation |
| BP | IBA | GO:0016477 | cell migration |
| BP | IBA | GO:0030154 | cell differentiation |
| BP | IBA | GO:0038083 | peptidyl-tyrosine autophosphorylation |
| BP | TAS | GO:0038128 | ERBB2 signaling pathway |
| BP | IBA | GO:0042127 | regulation of cell proliferation |
| BP | IBA | GO:0045087 | innate immune response |
| CC | TAS | GO:0005829 | cytosol |
| CC | IBA | GO:0031234 | extrinsic component of cytoplasmic side of plasma membrane |
Gene expression in normal tissue: MATK
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in MATK
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-1227986 | Signaling by ERBB2 |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-8863795 | Downregulation of ERBB2 signaling |
| reactome | R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases |
| pid | kitpathway | Signaling events mediated by Stem cell factor receptor (c-Kit) |
| pid | trkrpathway | Neurotrophic factor-mediated Trk receptor signaling |
| netpath | Pathway_KitReceptor | KitReceptor |
| kegg | hsa04722 | Neurotrophin signaling pathway - Homo sapiens (human) |
| wikipathways | WP304 | Kit receptor signaling pathway |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD280 | CYTOCHALASIN B | 3 |
| iGMDRD634 | SCHEMBL2608041 | 3 |
| iGMDRD71 | Sparfosic acid | 3 |
| iGMDRD341 | Triacsin c | 3 |
| iGMDRD314 | Tanespimycin | 3 |
| iGMDRD144 | NSC95397 | 9 |
| iGMDRD150 | RITA | 6 |
| iGMDRD781 | Sirolimus | 3 |
| iGMDRD701 | NVP-AUY922 | 3 |
| iGMDRD405 | PIK-75 | 3 |
| iGMDRD494 | Neopeltolide | 3 |
| iGMDRD579 | PF750 | 3 |
| iGMDRD60 | Quinoclamine | 3 |
| iGMDRD300 | Tozasertib | 9 |
| iGMDRD872 | BRD7137 | 3 |
| iGMDRD74 | Idarubicin | 3 |
| iGMDRD887 | Compound 23 citrate | 3 |
| iGMDRD188 | Piperlongumine | 6 |
| iGMDRD506 | Fedratinib | 4 |
| iGMDRD577 | BIX01294 | 3 |
| iGMDRD329 | Merck60 | 9 |
| iGMDRD171 | Pemetrexed | 3 |
| iGMDRD441 | TW 37 | 3 |
| iGMDRD318 | PAC-1 | 3 |
| iGMDRD474 | Avrainvillamide | 6 |
| iGMDRD271 | Brefeldin A | 3 |
| iGMDRD158 | NSC141540 | 3 |
| iGMDRD255 | SB225002 | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in MATK
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.